Adam's Take

Aurinia Pharma’s takeout hopes dim with new legal challenge to key drug patent

Aurinia Pharma’s takeout hopes dim with new legal challenge to key drug patent

Takeover speculation has swirled around Aurinia Pharmaceuticals since late 2019 when its lead drug, Lupkynis, proved to be an effective treatment for lupus nephritis in a pivotal Phase 3 clinical trial. After Aurinia secured Lupkynis’ U.S. approval in January 2021, shareholders practically demanded its management team put the company up for sale, rather than try to sell the drug on its own.

But despite more than a few rumors and false alarms, Aurinia remains un-bought. This week, a problematic impediment to the company’s sale surfaced: Lupkynis’ patent life might not be as strong or long as it had hoped.

Most Popular

To Top